Linas, Benjamin P.

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 332

Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture–recapture analysis

Barocas, J. A., White, L. F., Wang, J., Walley, A. Y., LaRochelle, M. R., Bernson, D., Land, T., Morgan, J. R., Samet, J. H., & Linas, B. P. (2018) · American Journal of Public Health

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 164

Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort

Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019) · Drug and Alcohol Dependence

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 159

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 101

Projected estimates of opioid mortality after community-level interventions.

Linas, B. P., Savinkina, A., Madushani, R. W. M. A., Wang, J., Eftekhari Yazdi, G., Chatterjee, A., Walley, A. Y., Morgan, J. R., Epstein, R. L., Assoumou, S. A., et al. (2021) · JAMA Network Open

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 72

Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021) · Drug and Alcohol Dependence

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 67

Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States

Losina, E., Hyle, E. P., Borre, E. D., Linas, B. P., Sax, P. E., Weinstein, M. C., Rusu, C., Ciaranello, A. L., Walensky, R. P., & Freedberg, K. A. (2017) · Clinical Infectious Diseases

HIV-related health complications and treatmentsHIV/AIDS Research and Interventions

Cited by 62

Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Linas, B. P., Wong, A. Y., Schackman, B. R., Kim, A. Y., & Freedberg, K. A. (2012) · Clinical Infectious Diseases

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 61

Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design

Morgan, J. R., Quinn, E. K., Chaisson, C. E., Ciemins, E., Stempniewicz, N., White, L. F., Linas, B. P., Walley, A. Y., & LaRochelle, M. R. (2022) · Medical Care

Opioid Use Disorder TreatmentHealthcare Policy and Management

Cited by 30

Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island

Zang, X., Bessey, S. E., Krieger, M. S., Hallowell, B. D., Koziol, J. A., Nolen, S., Behrends, C. N., Murphy, S. M., Walley, A. Y., Linas, B. P., et al. (2022) · JAMA Network Open

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 26

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

Flam-Ross, J. M., Marsh, E., Weitz, M., Savinkina, A., Schackman, B. R., Wang, J., Madushani, R. W. M. A., Morgan, J. R., Barocas, J. A., Walley, A. Y., et al. (2023) · JAMA Network Open

Opioid Use Disorder TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 21

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 19